Sebolt-Leopold and colleagues design and develop a small-molecule inhibitor that can target both epidermal growth factor receptor and phosphatidylinositol 3-OH kinase, which can be leveraged to overcome resistance to targeted therapies in vivo.
- Christopher E. Whitehead
- Elizabeth K. Ziemke
- Judith S. Sebolt-Leopold
